Brain Tumor Drugs Market (Detailed Analysis and Current Scenario) Global Outlook & Forecast 2022-2030
The increasing occurrence of brain tumor cases, both benign or malignant has greatly impacted the global brain tumor drugs market growth. As there is an increased rate of diagnosis of tumors due to the availability of advanced technologies in diagnostics, there is an increased demand for more effective drugs. Thus, many key players are investing in R&D activities to develop more innovative drugs and therapies. The governments of various economies are supported by funding the research to facilitate the development of treatments. This support thus leads increase in pipeline candidates for brain tumor drugs.
The global brain tumor drugs market was pegged at US$ 3.24 million in 2021. The market is expected to witness a CAGR of 9.4% from 2022 to 2030.
Over the years, there is a significant rise in the incidence of brain tumors. This may be due to factors such as exposure to radiation, rise in the elderly population, changes in lifestyle, environmental pollution, etc. According to the National Center for Biotechnology Information (NCBI), United States research, the incidence of glioblastoma tumor is 0.59-5 per 100,000 population. This rate is rapidly increasing globally. Thus, this incidence rate has a direct influence on demand for brain tumor drugs and hence propelling the market growth.
Download Sample PDF Brochure:
https://growthplusreports.com/inquiry/request-sample/brain-tumor-drugsmarket/7782
Key players:
AstraZeneca plc
Johnson & Johnson Inc.
Merck & Co.
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Y-mAbs Therapeutics, Inc.
Shimadzu Corporation
Bristol-Myers Squibb
Bayer AG
Dr. Reddy’s Laboratories Ltd.
By Indication: Glioblastoma
Meningioma
Pituitary Adenoma
By Therapy Type:
Chemotherapy
Immunotherapy
Targeted therapy
Regional Analysis-
The Asia-Pacific market is anticipated to grow at a higher CAGR during the forecast period.
Major factors contributing to the growth of Brain Tumor Drugs market in this region include the rising incidence of chronic infectious diseases, rising awareness regarding growing applications of Brain Tumor Drugs, and increasing research activities in the field of Brain Tumor Drugs.
The emergence of local players and new product launches has also played a critical role in boosting the Brain Tumor Drugs market in this region.
Browse the full report now: https://growthplusreports.com/report/brain-tumordrugs-market/7782
Key Questions Answered in the Report Include:
(1) This report gives all the information about the industry analysis, revenue, and overview, of this market.
(2) What will be the rate of increase in market size and growth rate by the end of the forecast period?
(3) What are the major global Brain Tumor Drugs Market trends influencing the development of the market?
(4) What are the vital results of SWOT analysis of the major players operating in the Brain Tumor Drugs Market?
(5) What are the potential growth opportunities and threats faced by Major competitors in the market?
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.